- Report
- April 2023
- 107 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- August 2022
- 115 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- May 2025
- 110 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- May 2025
- 110 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- February 2024
- 113 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- June 2026
- 115 Pages
Mexico
From €3619EUR$3,999USD£3,091GBP
- Report
- April 2023
- 119 Pages
Global
From €4072EUR$4,500USD£3,478GBP
- Report
- June 2025
- 229 Pages
Global
From €2262EUR$2,500USD£1,932GBP
- Report
- December 2024
- 196 Pages
Global
From €2262EUR$2,500USD£1,932GBP
- Report
- August 2024
- 184 Pages
Global
From €2262EUR$2,500USD£1,932GBP
- Report
- July 2021
- 120 Pages
Global
From €2262EUR$2,500USD£1,932GBP
- Report
- May 2025
- 120 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- May 2025
- 110 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- July 2024
- 170 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- February 2024
- 179 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- April 2023
- 110 Pages
Global
From €4298EUR$4,750USD£3,671GBP
- Report
- June 2025
- 400 Pages
Global
From €4478EUR$4,949USD£3,825GBP
- Report
- April 2024
- 140 Pages
Global
From €4496EUR$4,969USD£3,841GBP
- Report
- November 2023
- 209 Pages
Global
From €4027EUR$4,450USD£3,440GBP
- Report
- November 2023
- 176 Pages
Global
From €4027EUR$4,450USD£3,440GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more